<?xml version="1.0" encoding="UTF-8"?><safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>JP-MLMSERVICE-TESTCASE-20150427-45</safetyreportid>
		<primarysourcecountry>JP</primarysourcecountry>
		<occurcountry>JP</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20150416</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20150413</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20150413</receiptdate>
		<additionaldocument>2</additionaldocument>
		<documentlist/>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<authoritynumb/>
		<companynumb>JP-MLMSERVICE-TESTCASE-20150427-45</companynumb>
		<duplicate/>
		<casenullification/>
		<nullificationreason/>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle>Dr</reportertitle>
			<reportergivename>D</reportergivename>
			<reportermiddlename/>
			<reporterfamilyname>Takeuchi</reporterfamilyname>
			<reporterorganization>4400771</reporterorganization>
			<reporterdepartment/>
			<reporterstreet/>
			<reportercity/>
			<reporterstate/>
			<reporterpostcode>914-0024</reporterpostcode>
			<reportercountry>JP</reportercountry>
			<qualification>1</qualification>
			<literaturereference>Takeuchi D, et al. Clinical experience: Use of duloxetine in 2 patients with chronic pain. Japanese Journal of Psychiatric Treatment. 2015;30:415-419</literaturereference>
			<studyname/>
			<sponsorstudynumb/>
			<observestudytype/>
		</primarysource>
		<sender>
			<sendertype>6</sendertype>
			<senderorganization>MLMSERVICE</senderorganization>
			<senderdepartment>test</senderdepartment>
			<sendertitle>dr</sendertitle>
			<sendergivename>mlmtest</sendergivename>
			<sendermiddlename/>
			<senderfamilyname>test</senderfamilyname>
			<senderstreetaddress>test</senderstreetaddress>
			<sendercity>test</sendercity>
			<senderstate/>
			<senderpostcode>1</senderpostcode>
			<sendercountrycode>GB</sendercountrycode>
			<sendertel>12345</sendertel>
			<sendertelextension>3456</sendertelextension>
			<sendertelcountrycode>44</sendertelcountrycode>
			<senderfax>12345</senderfax>
			<senderfaxextension>3456</senderfaxextension>
			<senderfaxcountrycode>44</senderfaxcountrycode>
			<senderemailaddress>1@MLMSERVICE.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype/>
			<receiverorganization>EVTEST</receiverorganization>
			<receiverdepartment/>
			<receivertitle/>
			<receivergivename/>
			<receivermiddlename/>
			<receiverfamilyname/>
			<receiverstreetaddress/>
			<receivercity/>
			<receiverstate/>
			<receiverpostcode/>
			<receivercountrycode/>
			<receivertel/>
			<receivertelextension/>
			<receivertelcountrycode/>
			<receiverfax/>
			<receiverfaxextension/>
			<receiverfaxcountrycode/>
			<receiveremailaddress/>
		</receiver>
		<patient>
			<patientinitial/>
			<patientgpmedicalrecordnumb/>
			<patientspecialistrecordnumb/>
			<patienthospitalrecordnumb/>
			<patientinvestigationnumb/>
			<patientbirthdateformat/>
			<patientbirthdate/>
			<patientonsetage>80</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<gestationperiod/>
			<gestationperiodunit/>
			<patientagegroup/>
			<patientweight/>
			<patientheight/>
			<patientsex>2</patientsex>
			<lastmenstrualdateformat/>
			<patientlastmenstrualdate/>
			<patientmedicalhistorytext/>
			<resultstestsprocedures>(In July of an unspecified year (1 year after the onset of right shoulder pain))Hamilton Rating Scale for Depression (HAM-D) score, 6; McGill Pain Questionnaire (MPQ) score, 32.(In the middle of August of an unspecified year (1 year after the onset of right shoulder pain))HAM-D score, 2; MPQ score, 9.(In the early December of an unspecified year (1 year after the onset of right shoulder pain))HAM-D score, 3; MPQ score, 21.(In February of an unspecified year (2 years after the onset of right shoulder pain)) (Two months after the drug was resumed)HAM-D score, 2; MPQ score, 11.</resultstestsprocedures>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10012378</patientepisodename>
				<patientmedicalstartdateformat/>
				<patientmedicalstartdate/>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat/>
				<patientmedicalenddate/>
				<patientmedicalcomment/>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10040617</patientepisodename>
				<patientmedicalstartdateformat/>
				<patientmedicalstartdate/>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat/>
				<patientmedicalenddate/>
				<patientmedicalcomment/>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10064332</patientepisodename>
				<patientmedicalstartdateformat/>
				<patientmedicalstartdate/>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat/>
				<patientmedicalenddate/>
				<patientmedicalcomment/>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10054095</patientepisodename>
				<patientmedicalstartdateformat/>
				<patientmedicalstartdate/>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalenddateformat/>
				<patientmedicalenddate/>
				<patientmedicalcomment/>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>17.1</patientepisodenamemeddraversion>
				<patientepisodename>10028836</patientepisodename>
				<patientmedicalstartdateformat/>
				<patientmedicalstartdate/>
				<patientmedicalcontinue/>
				<patientmedicalenddateformat/>
				<patientmedicalenddate/>
				<patientmedicalcomment/>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Adverse event</primarysourcereaction>
				<reactionmeddraversionllt>17.1</reactionmeddraversionllt>
				<reactionmeddrallt>10021328</reactionmeddrallt>
				<reactionmeddraversionpt/>
				<reactionmeddrapt/>
				<termhighlighted>4</termhighlighted>
				<reactionstartdateformat/>
				<reactionstartdate/>
				<reactionenddateformat/>
				<reactionenddate/>
				<reactionduration/>
				<reactiondurationunit/>
				<reactionfirsttime/>
				<reactionfirsttimeunit/>
				<reactionlasttime/>
				<reactionlasttimeunit/>
				<reactionoutcome>2</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>Paxil Tablet</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb/>
				<drugauthorizationnumb/>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder>GSK</drugauthorizationholder>
				<drugstructuredosagenumb/>
				<drugstructuredosageunit/>
				<drugseparatedosagenumb/>
				<drugintervaldosageunitnumb/>
				<drugintervaldosagedefinition/>
				<drugcumulativedosagenumb/>
				<drugcumulativedosageunit/>
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform>Tablet</drugdosageform>
				<drugadministrationroute/>
				<drugparadministration/>
				<reactiongestationperiod/>
				<reactiongestationperiodunit/>
				<drugindicationmeddraversion/>
				<drugindication/>
				<drugstartdateformat/>
				<drugstartdate/>
				<drugstartperiod/>
				<drugstartperiodunit/>
				<druglastperiod/>
				<druglastperiodunit/>
				<drugenddateformat/>
				<drugenddate/>
				<drugtreatmentduration/>
				<drugtreatmentdurationunit/>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional/>
				<activesubstance>
					<activesubstancename>PAROXETINE HYDROCHLORIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10021328</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>17.1</drugreactionassesmeddraversion>
					<drugreactionasses>10021328</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>FELBINAC</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb/>
				<drugauthorizationnumb/>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder/>
				<drugstructuredosagenumb/>
				<drugstructuredosageunit/>
				<drugseparatedosagenumb/>
				<drugintervaldosageunitnumb/>
				<drugintervaldosagedefinition/>
				<drugcumulativedosagenumb/>
				<drugcumulativedosageunit/>
				<drugdosagetext>UNK mg, UNK</drugdosagetext>
				<drugdosageform/>
				<drugadministrationroute/>
				<drugparadministration/>
				<reactiongestationperiod/>
				<reactiongestationperiodunit/>
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10033371</drugindication>
				<drugstartdateformat/>
				<drugstartdate/>
				<drugstartperiod/>
				<drugstartperiodunit/>
				<druglastperiod/>
				<druglastperiodunit/>
				<drugenddateformat/>
				<drugenddate/>
				<drugtreatmentduration/>
				<drugtreatmentdurationunit/>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional/>
				<activesubstance>
					<activesubstancename>FELBINAC</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>LOXOPROFEN</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb/>
				<drugauthorizationnumb/>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder/>
				<drugstructuredosagenumb/>
				<drugstructuredosageunit/>
				<drugseparatedosagenumb/>
				<drugintervaldosageunitnumb/>
				<drugintervaldosagedefinition/>
				<drugcumulativedosagenumb/>
				<drugcumulativedosageunit/>
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform/>
				<drugadministrationroute/>
				<drugparadministration/>
				<reactiongestationperiod/>
				<reactiongestationperiodunit/>
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10033371</drugindication>
				<drugstartdateformat/>
				<drugstartdate/>
				<drugstartperiod/>
				<drugstartperiodunit/>
				<druglastperiod/>
				<druglastperiodunit/>
				<drugenddateformat/>
				<drugenddate/>
				<drugtreatmentduration/>
				<drugtreatmentdurationunit/>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional/>
				<activesubstance>
					<activesubstancename>LOXOPROFEN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PREGABALIN</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb/>
				<drugauthorizationnumb/>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder/>
				<drugstructuredosagenumb/>
				<drugstructuredosageunit/>
				<drugseparatedosagenumb/>
				<drugintervaldosageunitnumb/>
				<drugintervaldosagedefinition/>
				<drugcumulativedosagenumb/>
				<drugcumulativedosageunit/>
				<drugdosagetext/>
				<drugdosageform/>
				<drugadministrationroute/>
				<drugparadministration/>
				<reactiongestationperiod/>
				<reactiongestationperiodunit/>
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10033371</drugindication>
				<drugstartdateformat/>
				<drugstartdate/>
				<drugstartperiod/>
				<drugstartperiodunit/>
				<druglastperiod/>
				<druglastperiodunit/>
				<drugenddateformat/>
				<drugenddate/>
				<drugtreatmentduration/>
				<drugtreatmentdurationunit/>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional/>
				<activesubstance>
					<activesubstancename>PREGABALIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>ACETAMINOPHEN</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb/>
				<drugauthorizationnumb/>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder/>
				<drugstructuredosagenumb/>
				<drugstructuredosageunit/>
				<drugseparatedosagenumb/>
				<drugintervaldosageunitnumb/>
				<drugintervaldosagedefinition/>
				<drugcumulativedosagenumb/>
				<drugcumulativedosageunit/>
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform/>
				<drugadministrationroute/>
				<drugparadministration/>
				<reactiongestationperiod/>
				<reactiongestationperiodunit/>
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10033371</drugindication>
				<drugstartdateformat/>
				<drugstartdate/>
				<drugstartperiod/>
				<drugstartperiodunit/>
				<druglastperiod/>
				<druglastperiodunit/>
				<drugenddateformat/>
				<drugenddate/>
				<drugtreatmentduration/>
				<drugtreatmentdurationunit/>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional/>
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>DULOXETINE</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb/>
				<drugauthorizationnumb/>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder/>
				<drugstructuredosagenumb/>
				<drugstructuredosageunit/>
				<drugseparatedosagenumb/>
				<drugintervaldosageunitnumb/>
				<drugintervaldosagedefinition/>
				<drugcumulativedosagenumb/>
				<drugcumulativedosageunit/>
				<drugdosagetext/>
				<drugdosageform/>
				<drugadministrationroute/>
				<drugparadministration/>
				<reactiongestationperiod/>
				<reactiongestationperiodunit/>
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10033371</drugindication>
				<drugstartdateformat/>
				<drugstartdate/>
				<drugstartperiod/>
				<drugstartperiodunit/>
				<druglastperiod/>
				<druglastperiodunit/>
				<drugenddateformat/>
				<drugenddate/>
				<drugtreatmentduration/>
				<drugtreatmentdurationunit/>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional/>
				<activesubstance>
					<activesubstancename>DULOXETINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>DULOXETINE</medicinalproduct>
				<obtaindrugcountry>JP</obtaindrugcountry>
				<drugbatchnumb/>
				<drugauthorizationnumb/>
				<drugauthorizationcountry>JP</drugauthorizationcountry>
				<drugauthorizationholder/>
				<drugstructuredosagenumb/>
				<drugstructuredosageunit/>
				<drugseparatedosagenumb/>
				<drugintervaldosageunitnumb/>
				<drugintervaldosagedefinition/>
				<drugcumulativedosagenumb/>
				<drugcumulativedosageunit/>
				<drugdosagetext/>
				<drugdosageform/>
				<drugadministrationroute/>
				<drugparadministration/>
				<reactiongestationperiod/>
				<reactiongestationperiodunit/>
				<drugindicationmeddraversion>17.1</drugindicationmeddraversion>
				<drugindication>10016323</drugindication>
				<drugstartdateformat/>
				<drugstartdate/>
				<drugstartperiod/>
				<drugstartperiodunit/>
				<druglastperiod/>
				<druglastperiodunit/>
				<drugenddateformat/>
				<drugenddate/>
				<drugtreatmentduration/>
				<drugtreatmentdurationunit/>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<drugadditional/>
				<activesubstance>
					<activesubstancename>DULOXETINE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This case was reported in a literature article and described the occurrence of ileus in a 80-year-old female patient who received paroxetine hydrochloride (Paxil) tablet for an unknown indication. (Takeuchi D, et al.. Clinical experience: Use of duloxetine in 2 patients with chronic pain. Japanese Journal of Psychiatric Treatment 2015; 30: 415-419.)Co-suspect products included felbinac for pain, loxoprofen for pain, pregabalin for pain, paracetamol (Acetaminophen) for pain and duloxetine for pain and feeling anxious.Concurrent medical conditions included depression, shoulder pain, complex regional pain syndrome, neuropathic pain and neck pain.On an unknown date, the patient started Paxil at an unknown dose and frequency, felbinac 70 mg daily, loxoprofen 180 mg daily, pregabalin at an unknown dose and frequency, Acetaminophen 600 mg daily and duloxetine at an unknown dose and frequency. On an unknown date, unknown after starting Paxil, the patient experienced ileus (serious criteria GSK medically significant). Paxil was discontinued (Dechallenge was positive). Rechallenge with Paxil was unknown. Felbinac was discontinued (Dechallenge was positive). Rechallenge with felbinac was unknown. Loxoprofen was discontinued (Dechallenge was positive). Rechallenge with loxoprofen was unknown. Pregabalin was discontinued (Dechallenge was positive). Rechallenge with pregabalin was unknown. Acetaminophen was discontinued (Dechallenge was positive). Rechallenge with Acetaminophen was unknown. Duloxetine was discontinued (Dechallenge was positive). Rechallenge with duloxetine was unknown. On an unknown date, the outcome of the ileus was recovering/resolving.The reporter considered the ileus to be related to Paxil.On 26 July of an unspecified year (2 years before), the patient was diagnosed with depression.On 04 August of the same year, she was admitted to the reporter's hospital. She started receiving paroxetine, and remission of the depression was achieved approximately half a year later.However, her family members showed reluctance to take care of her at home and her hospitalization was prolonged.Subsequent course: Around September of an unspecified year, right shoulder pain developed triggered by pushing a handcart in the ward, and the pain was gradually aggravated.Radiography was performed in the reporter's hospital but no fractures were shown. Topical treatment with felbinac at 70 mg/day and oral treatment with loxoprofen at 180 mg/day were started for the pain, but the treatments were ineffective as expected.Blood count test, biochemical test, thyroid function test, electrocardiography, chest X-ray, head computerized tomography (CT) scan, and electroencephalography were performed as precautionary measures, but no abnormalities were observed in any of these examinations.She was referred to a physician of a pain clinic accordingly, and was diagnosed as having 'pain possibly similar to complex regional pain syndrome' and started to undergo periodic stellate ganglion blocks regularly.However, she stated that the pain abated a little immediately after the injections but returned as usual after a while.In around February of an unspecified year (1 year later), she started to complain of left posterior cervical pain. Possible relationship to neuropathic pain due to cervical spondylosis was indicated at the pain clinic, and she started taking pregabalin at 75 mg and acetaminophen at 600 mg/day in addition to the treatment with stellate ganglion blocks she had received.However, her pain did not improve much. The physician of the pain clinic asked the reporter's department to use an antidepressant drug. Her attending physician explained the patient and her family about the off-label use of duloxetine in expectation of improvement of the pain and anxiety as well as the risk of adverse reactions to duloxetine. They fully understood the explanation and consented to the treatment.Before the start of duloxetine, Hamilton Rating Scale for Depression (HAM-D) score was 6 and McGill Pain Questionnaire (MPQ) score was 32. In the early July of the same year, duloxetine at 20 mg/day was added, and the dose of the drug was escalated every 2 weeks to 60 mg/day. In the middle of August of the same year, she stated that her pain reduced by 90%.HAM-D and MPQ scores improved to 2 and 9, respectively. However, she had ileus in October of the same year and was transferred to Hospital B in the end of the same month. Drug-induced ileus was found at Hospital B, and all the drugs were discontinued.As the ileus improved by November of the same year, she was readmitted to the reporter's hospital. She had no mood disorder or chronic pain at that time.The patient did not meet the diagnostic criteria of major depression. However, considering the prolonged hospitalization and a history of depression, the possibility that she started to have depressive symptoms which had not meet diagnostic criteria of major depression yet before the start of duloxetine could not be ruled out.</narrativeincludeclinical>
				<reportercomment/>
				<senderdiagnosismeddraversion/>
				<senderdiagnosis/>
				<sendercomment/>
			</summary>
		</patient>
	</safetyreport>